Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.
Developer of life sciences technology intended to develop highly effective and differentiated treatments for cystic fibrosis. The company is developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with cystic fibrosis, enabling patients with best-in-class efficacy and reach and long-term benefit for people with cystic fibrosis.
Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.
CDR-Life is a Zurich-based biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology. Our facilities are located in the Bio-Technopark in Schlieren-Zurich, Switzerland
Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.
Ocelot Bio brings new treatment options to patients with severe liver disease. The company was founded in 2020 and is headquartered in San Diego, California.
Plexium, Inc. is a biotechnology company based in San Diego, California, established in 2017. The company specializes in drug development, focusing on the identification of small molecules that modulate E3 ligases for therapeutic applications in cancer and neurodegenerative diseases. Plexium employs a DNA-encoded library platform to conduct high-throughput screening, utilizing cell-based assays to discover molecular glues that can alter E3 ligase substrate recognition, thereby inducing, inhibiting, or modulating protein degradation. This innovative approach allows Plexium to selectively target various cancers, including small cell lung and breast tumors, while also exploring mechanisms to enhance immune responses through E3 ligase modulation.
Qvella Corporation is a Toronto-based molecular diagnostics company established in 2009 by a team of scientists and engineers. The company focuses on advancing sample preparation and detection technologies in clinical microbiology, aiming to significantly reduce the time required to obtain results. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a unique electrical lysing method known as e-lysis™, allowing for the direct and fully automated rapid detection of infectious agents from unenriched biological samples. By providing actionable results in clinically relevant time frames, Qvella seeks to improve patient outcomes and transform medical practices in the field of microbiology.
Asher Biotherapeutics, Inc. is a biotechnology company focused on developing immunotherapy drugs for cancer treatment. Founded in 2019 and headquartered in South San Francisco, California, the company aims to create innovative therapeutic solutions to improve patient outcomes in oncology. Asher Bio leverages advanced technologies and research to enhance the effectiveness of immune-based therapies, positioning itself as a key player in the evolving field of cancer treatment.
Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.
Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.
New Equilibrium Biosciences focuses on the research and development of therapeutic drugs aimed at treating cancer, neurodegenerative diseases, and other medical conditions. The company specializes in targeting intrinsically disordered proteins (IDPs), which play a significant role in various disorders. By integrating artificial intelligence with quantum chemistry, New Equilibrium leverages biophysical experiments to explore opportunities for structure-based drug design. This approach includes the creation of compound libraries specifically for IDPs, allowing for the identification of potential drug candidates that can interact with transient binding pockets on these proteins. Through its innovative platform, New Equilibrium aims to enhance drug discovery processes and improve treatment options within the healthcare sector.
Scribe Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics using CRISPR technology to address genetic disorders. Founded in 2017 and based in Berkeley, California, Scribe specializes in engineering CRISPR enzymes known as X-Editing (XE) molecules, which enhance the efficacy, specificity, and deliverability of genome editing compared to existing methods. The company's proprietary platform enables the creation of custom-engineered enzymes and delivery systems, facilitating precision targeting within the genome. Scribe Therapeutics aims to establish CRISPR-based therapies as a standard in clinical care, expanding access to transformative treatments for a wide range of conditions, including immuno-oncology and degenerative disorders. Through its commitment to overcoming the limitations of current genome editing technologies, Scribe Therapeutics is poised to make substantial contributions to human therapeutics.
Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.
Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.
Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers in patients of all ages, with an initial emphasis on pediatric patients. Founded in 2018 and headquartered in South San Francisco, California, the company aims to address the critical needs of children and adults diagnosed with cancer by creating innovative treatments derived from the biology of childhood cancer. Day One Biopharmaceuticals prioritizes programs that can be swiftly brought to market, thereby providing timely options for families facing cancer diagnoses. Its lead product candidate, DAY101, is an oral, brain-penetrant pan-RAF kinase inhibitor designed to target specific cancer types. The company seeks to license and acquire promising therapeutic products from research institutions and other biotechnology and pharmaceutical companies, striving to enhance the treatment landscape for underserved populations.
Locanabio, Inc. develops RNA-targeted gene therapies to treat a spectrum of underserved diseases. It offers therapies for neuromuscular, neurodegeneration, and ophthalmology diseases. Locanabio, Inc. was formerly known as Locana, Inc. and changed its name to Locanabio, Inc. in July 2020. The company was founded in 2016 and is based in San Diego, California.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
LianBio is a biopharmaceutical company based in Shanghai, China, with an additional office in Princeton, New Jersey. Founded in 2019, the company focuses on the discovery and development of therapeutic drugs aimed at treating oncology and cardiorenal diseases, as well as other medical conditions. LianBio's mission is to enhance access to innovative medicines by partnering with leading organizations in the field to leverage advanced scientific discoveries. The company is dedicated to addressing unmet medical needs in Greater China and other Asian markets by in-licensing assets and building a diverse pipeline of clinically validated product candidates. Its portfolio aims to establish new standards of care across various therapeutic areas, including cardiovascular, oncology, ophthalmology, inflammatory diseases, and respiratory conditions.
Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.
Qvella Corporation is a Toronto-based molecular diagnostics company established in 2009 by a team of scientists and engineers. The company focuses on advancing sample preparation and detection technologies in clinical microbiology, aiming to significantly reduce the time required to obtain results. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a unique electrical lysing method known as e-lysis™, allowing for the direct and fully automated rapid detection of infectious agents from unenriched biological samples. By providing actionable results in clinically relevant time frames, Qvella seeks to improve patient outcomes and transform medical practices in the field of microbiology.
Saniona is a research and development company with low burn rate, a world class team and high ambitions.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Cybin is a biopharmaceutical company dedicated to developing safe and effective therapeutics using psychedelic and medicinal mushrooms. The company focuses on creating psilocybin-based products in regions where such substances are permitted, while also conducting clinical studies across North America and other areas through collaborations with academic and institutional partners. Cybin's efforts encompass the advancement of psychedelic-based therapies, innovative delivery mechanisms, and the development of novel compounds aimed at addressing a range of mental health issues, including various psychiatric and neurological conditions.
Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.
Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for oncology and other medical conditions. Its primary product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy aimed at treating multiple myeloma by targeting the B-cell maturation antigen. The company is actively conducting clinical trials to assess this therapy as an earlier treatment option and to compare its effectiveness against standard triplet therapy in patients resistant to Revlimid. Additionally, Legend Biotech has a diverse portfolio of earlier-stage autologous product candidates that address various cancers, including non-Hodgkin lymphoma, acute myeloid leukemia, and T cell lymphoma. The company is also developing an allogeneic CAR-T product candidate targeting CD20, currently in a Phase 1 clinical trial in China. Besides its focus on blood cancers, Legend Biotech is exploring therapies for solid tumors and infectious diseases. Founded in 2014 and based in Somerset, New Jersey, Legend Biotech operates as a subsidiary of Genscript Biotech Corporation.
Qvella Corporation is a Toronto-based molecular diagnostics company established in 2009 by a team of scientists and engineers. The company focuses on advancing sample preparation and detection technologies in clinical microbiology, aiming to significantly reduce the time required to obtain results. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a unique electrical lysing method known as e-lysis™, allowing for the direct and fully automated rapid detection of infectious agents from unenriched biological samples. By providing actionable results in clinically relevant time frames, Qvella seeks to improve patient outcomes and transform medical practices in the field of microbiology.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
SeLux Diagnostics, Inc. is focused on advancing antibiotic susceptibility testing and infectious disease diagnostics through its innovative phenotyping platform. Founded in 2014 and located in Charlestown, Massachusetts, the company employs a unique synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing. This platform significantly improves the accuracy and timeliness of diagnosing infections, enabling healthcare providers to prescribe targeted and personalized antibiotic therapies. By facilitating informed treatment decisions, SeLux Diagnostics aims to enhance patient care, save lives, and improve overall health outcomes in hospital settings.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
Precision BioSciences, Inc. is a biotechnology company that specializes in genome editing, utilizing its proprietary ARCUS platform to develop therapeutic and food products. The Therapeutic segment focuses on creating allogeneic CAR T immunotherapies aimed at treating various cancers, including acute lymphoblastic leukemia and multiple myeloma, with several candidates currently in clinical trials. Notable product candidates include PBCAR0191, targeting CD19, and PBCAR269A, targeting BCMA. Additionally, the company is engaged in in vivo gene correction and has collaborations for developing treatments for chronic Hepatitis B. The Food segment aims to innovate in food and nutrition products. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences is committed to translating advanced genome editing technology into impactful medical and agricultural solutions.
CiVi Biopharma is a clinical-stage biotechnology company focused on developing innovative therapies for cardiovascular and metabolic diseases, particularly those with significant unmet medical needs. The company is advancing multiple assets in its pipeline, including Intravenous Iloprost, which is currently undergoing Phase 3 trials for the treatment of Systemic Sclerosis. By concentrating on both cardiovascular and rare diseases, CiVi Biopharma aims to provide valuable therapeutic options that enhance patient care and improve health outcomes.
Synthorx, Inc. is a biopharmaceutical company based in La Jolla, California, that specializes in developing innovative protein therapeutics through synthetic biology. The company focuses on creating novel cytokine Synthorin programs aimed at treating cancer and autoimmune disorders. Its lead candidate, THOR-707, is a modified version of recombinant human IL-2 being tested for various solid tumors, both as a monotherapy and in combination with immune checkpoint inhibitors. Additionally, Synthorx is developing Synthorins for other indications, including IL-10 for immuno-oncology and IL-15 as an immunoregulatory cytokine. The company leverages proprietary engineered organisms to produce these advanced proteins with high fidelity, enhancing their efficacy, safety, and convenience for patients. Founded in 2014 with technology licensed from The Scripps Research Institute, Synthorx has attracted investment from various venture capital firms and operates as a subsidiary of Sanofi.
Qvella Corporation is a Toronto-based molecular diagnostics company established in 2009 by a team of scientists and engineers. The company focuses on advancing sample preparation and detection technologies in clinical microbiology, aiming to significantly reduce the time required to obtain results. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a unique electrical lysing method known as e-lysis™, allowing for the direct and fully automated rapid detection of infectious agents from unenriched biological samples. By providing actionable results in clinically relevant time frames, Qvella seeks to improve patient outcomes and transform medical practices in the field of microbiology.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
Synthorx, Inc. is a biopharmaceutical company based in La Jolla, California, that specializes in developing innovative protein therapeutics through synthetic biology. The company focuses on creating novel cytokine Synthorin programs aimed at treating cancer and autoimmune disorders. Its lead candidate, THOR-707, is a modified version of recombinant human IL-2 being tested for various solid tumors, both as a monotherapy and in combination with immune checkpoint inhibitors. Additionally, Synthorx is developing Synthorins for other indications, including IL-10 for immuno-oncology and IL-15 as an immunoregulatory cytokine. The company leverages proprietary engineered organisms to produce these advanced proteins with high fidelity, enhancing their efficacy, safety, and convenience for patients. Founded in 2014 with technology licensed from The Scripps Research Institute, Synthorx has attracted investment from various venture capital firms and operates as a subsidiary of Sanofi.
Qvella Corporation is a Toronto-based molecular diagnostics company established in 2009 by a team of scientists and engineers. The company focuses on advancing sample preparation and detection technologies in clinical microbiology, aiming to significantly reduce the time required to obtain results. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a unique electrical lysing method known as e-lysis™, allowing for the direct and fully automated rapid detection of infectious agents from unenriched biological samples. By providing actionable results in clinically relevant time frames, Qvella seeks to improve patient outcomes and transform medical practices in the field of microbiology.
Wave Life Sciences
Series B in 2015
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.
Calimmune, Inc. is a clinical-stage company based in Tucson, Arizona, specializing in gene therapies for individuals living with human immunodeficiency virus (HIV). The company is developing Cal-1, a gene-based stem cell therapy designed to protect patients from progressing to AIDS. This innovative therapy aims to control HIV infection through a dual mechanism: it reduces the production of CCR5, a protein that facilitates HIV's ability to infect cells, and prevents viral fusion, thereby blocking the virus from entering cells. Currently, Cal-1 is undergoing Phase I/II clinical studies to evaluate its effectiveness. Calimmune focuses on addressing the diverse needs of individuals at various stages of HIV infection, emphasizing the importance of tailored treatments for those with different levels of treatment experience. Founded in 2000, Calimmune operates as a subsidiary of CSL Behring LLC.
Precision BioSciences, Inc. is a biotechnology company that specializes in genome editing, utilizing its proprietary ARCUS platform to develop therapeutic and food products. The Therapeutic segment focuses on creating allogeneic CAR T immunotherapies aimed at treating various cancers, including acute lymphoblastic leukemia and multiple myeloma, with several candidates currently in clinical trials. Notable product candidates include PBCAR0191, targeting CD19, and PBCAR269A, targeting BCMA. Additionally, the company is engaged in in vivo gene correction and has collaborations for developing treatments for chronic Hepatitis B. The Food segment aims to innovate in food and nutrition products. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences is committed to translating advanced genome editing technology into impactful medical and agricultural solutions.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Wave Life Sciences
Series A in 2015
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.
Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer, particularly in the fields of hematology and oncology. Its lead candidate, momelotinib, is a selective JAK1, JAK2, and ACVR1 inhibitor that has been evaluated in two Phase 3 trials for myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, currently undergoing two Phase 1/2 clinical trials to explore its potential as a monotherapy and in combination with other therapies. Additionally, Sierra is developing SRA141, a small molecule inhibitor of cell division cycle 7 kinase, which is in preclinical research stages. Founded in 2003 and headquartered in Vancouver, Canada, Sierra Oncology retains global commercialization rights for its product candidates and aims to achieve successful registration and commercialization of its innovative therapies targeting the DNA Damage Response network.
Lumena Pharmaceuticals focuses on developing oral therapeutics for rare liver diseases, aiming to enhance liver function and alleviate disease symptoms. The company's clinical-stage product candidates are designed to selectively target a transporter in the intestine, minimizing systemic absorption and reducing the risk of toxicities. Lumena's lead candidate, LUM001, has been thoroughly evaluated in over 12 clinical studies involving more than 1,400 subjects, positioning it for rapid advancement in clinical trials for both pediatric and adult patients with various forms of cholestatic liver disease. In addition to its primary objective of creating novel treatments for rare liver conditions, Lumena's innovative therapeutic approach also holds potential for addressing metabolic diseases affecting the liver, which represent a significant and growing health concern among both children and adults.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
AmpliPhi Biosciences is a biopharmaceutical company dedicated to developing bacteriophage-based therapies for bacterial infections, particularly those caused by drug-resistant strains. By leveraging naturally occurring viruses known as bacteriophages, the company aims to offer an innovative treatment approach that addresses a broad range of bacterial diseases. AmpliPhi has established a drug development and manufacturing platform that facilitates the rapid creation and production of various phage therapies. The initial focus of its research and development efforts is on treating acute and chronic infections in the lung, sinus, and gastrointestinal areas. The company operates in multiple locations, including Richmond, Virginia, Colworth Science Park in the United Kingdom, and near Sydney, Australia.
Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.
CellScape Corporation (formerly Saryna Medical Corp) is a privately funded company headquartered in Newark, California, in the heart of the biotech corridor of the San Francisco Bay Area. The Company has developed whole fetal cell technology to transform prenatal genetic testing using a simple blood test. Their vision is to make comprehensive prenatal genetic testing available to every woman without requiring an invasive procedure that might put the fetus at risk. Their leadership team is accomplished in bringing innovative, cost-effective medical and molecular diagnostics to market.
OvaScience, Inc. was a fertility company dedicated to developing and commercializing innovative treatment options for women facing infertility challenges. The company focused on its patented technology involving the discovery of egg precursor (EggPC) cells, which aimed to transform fertility treatments. Key offerings included OvaPrime, which sought to restore egg production by utilizing a woman’s own EggPC cells; OvaTure, designed to mature these cells into fertilizable eggs outside the body; and AUGMENT, which enhanced fertilization and pregnancy rates by incorporating mitochondria from a woman’s EggPC cells. Founded in 2011 and headquartered in Waltham, Massachusetts, OvaScience was co-founded by notable figures from the life sciences field and was backed by prominent investors. In December 2018, OvaScience was acquired by Millendo Therapeutics in a reverse merger transaction.
Seres Health, now known as Seres Therapeutics, Inc., is a clinical-stage therapeutics company focused on the development of microbiome-based drugs aimed at treating various diseases associated with dysbiosis. The company specializes in Ecobiotic therapeutics designed to restore health by repairing the microbiome's function. Its lead product candidate, SER-109, is currently in Phase III clinical trials to prevent the recurrence of Clostridium difficile infection (CDI). Additionally, Seres is advancing several other candidates, including SER-287, which is in a Phase IIb study for ulcerative colitis, and SER-401, currently in Phase Ib trials for use in combination with checkpoint inhibitors in metastatic melanoma patients. Other candidates under development include SER-262 for initial CDI recurrence and SER-155 for modulating the microbiome in patients post-stem cell transplants. The company collaborates with organizations like Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and was founded in 2010 in Cambridge, Massachusetts.
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.